Echo Street Capital Management’s Fate Therapeutics FATE Stock Holding History

Echo Street Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-49,073	Closed	-$495K	–	529
2022 Q4	$495K	Buy	49,073 +12,715	+35%	+$239K	﹤0.01%	283
2022 Q3	$815K	Buy	+36,358	New	+$1.05M	0.01%	185
2021 Q3	–	Sell	-2,865	Closed	-$249K	–	668
2021 Q2	$249K	Sell	2,865 -1,756	-38%	-$142K	﹤0.01%	517
2021 Q1	$381K	Buy	+4,621	New	+$443K	﹤0.01%	371

Other funds holding FATE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Echo Street Capital Management's FATE Position: Q1 2023 in Review

Echo Street Capital Management sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 49,073 shares — an estimated $495K sold.

Echo Street Capital Management first reported a position in FATE in Q1 2021 and held it in 4 quarters. The position peaked at $815K in Q3 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

Echo Street Capital Management reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
Echo Street Capital Management sold 49,073 Fate Therapeutics shares in Q1 2023, an estimated $495K.
Echo Street Capital Management first reported a position in Fate Therapeutics in Q1 2021 and held it in 4 quarters.
Echo Street Capital Management's Fate Therapeutics position peaked at $815K in Q3 2022.
181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Echo Street Capital Management's 13F filing for Q1 2023, filed 15 May 2023.